James Nam, PharmD

In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.

Investigators examined the impact of online symptom self-management on chronic pain symptoms associated with breast cancer survivorship.

Tamoxifen or exemestane plus ovarian suppression more effectively increases survival than tamoxifen alone for premenopausal women with breast cancer.

High-dose melphalan is a frequently before ASCT in MM, but is associated with high rates of adverse events.

Researchers accessed the SEER database and evaluated the population-based cancer survival data of 31,866 pediatric patients between the ages of 0 and 19.

ESMO has released a consensus on evidence-based criteria and proposed a classification system to prioritize genomic alterations as markers to select cancer patients for targeted therapies.

FDA upgraded the approval of pembrolizumab in combination with pemetrexed and platinum chemotherapy as a first-line treatment for patients with metastatic, nonsquamous NSCLC with no EGFR or ALK genomic tumor aberrations from accelerated to regular approval.

Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.

The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.

A single-center retrospective study determined the safety of IV hydration before and oral hydration after cisplatin therapy to prevent nephrotoxicity in patients with lung cancer vs IV hydration both before and after therapy.